Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 30, 2015 5:41 AM ET

Healthcare Equipment and Supplies

Company Overview of NeoChord, Inc.

Company Overview

NeoChord, Inc., a medical device company, focuses on minimally invasive mitral valve repair solutions. It develops a proprietary device that allows mitral valve repair to be performed on a beating heart through a two to three inch incision between the ribs in patients with severe, degenerative mitral valve regurgitation. The company offers NeoChord DS1000, a disposable device that is intended to replace damaged chordae by delivering artifical chordae tendinae or "neochords" in a beating heart. It primarily serves customers in Europe. The company was founded in 2007 and is based in Eden Prairie, Minnesota.

7700 Equitable Drive

Suite 206

Eden Prairie, MN 55344

United States

Founded in 2007





Key Executives for NeoChord, Inc.

Chief Executive Officer and President
Age: 48
Contract Chief Financial Officer
Vice President of Research and Development
Director of Quality
Vice President of Clinical Affairs, Regulatory and Quality
Age: 56
Compensation as of Fiscal Year 2015.

NeoChord, Inc. Key Developments

NeoChord Appoints Lori Adels as Vice President of Clinical Affairs, Regulatory and Quality

NeoChord, Inc. has appointed Lori Adels, Ph.D. as Vice President of Clinical Affairs, Regulatory and Quality. In this role, Dr. Adels will lead the company’s efforts to design and execute a pivotal trial for U.S. Food and Drug Administration (FDA) approval of its disposable device for minimally invasive, percutaneous mitral valve repair. By expanding the reach of this technology, NeoChord will continue to enhance the level of care provided to patients with degenerative mitral valve regurgitation. Most recently, Dr. Adels served as Executive Vice President of Regulatory and Clinical at Experien Group, where she was responsible for developing clients’ regulatory and clinical strategies; overseeing U.S. and international submissions; and providing regulatory support for product development, manufacturing and post-market compliance.

Neochord, Inc. Announces Management Changes

NeoChord, Inc. announced appointment of David H. Chung as President and CEO, effective immediately, replacing John Seaberg, who resigned. NeoChord also announced that Michael Fulton has been elected as Chairman of the Board. Most recently, David Chung served as Chief Commercial Officer at AcelRx Pharmaceuticals, Inc. Michael Fulton is a Managing Director at Hopen Life Science Ventures, has over twenty years of experience in the life sciences.

Similar Private Companies By Industry

Company Name Region
EBI, LLC United States
Ostial Solutions, LLC United States
Senior Scientific LLC United States
Plasmology4, Inc. United States
CyMedica Orthopedics, Inc. United States

Recent Private Companies Transactions

Private Placement
May 11, 2015
Private Placement
February 2, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact NeoChord, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at